niraparib

Patients in the intention-to-treat population who received niraparib had a median progression-free survival of 24.8 months, while patients who received placebo had a median progression-free survival of 8.3 months.

According to Dr. Venu Madhav Konala, MD, if a patient has achieved a complete response, the treatment is typically stopped after 2 years. However, if the patient has a partial response and there are 1 or 2 remaining lesions, Dr. Konala usually recommends performing a biopsy to determine if there is still active disease present.

Based on clinical trials and the summary of product characteristics, it is suggested that niraparib does not have any adverse effects on the kidney2-4, 6, 7.

Dr. stated that patients given Zejula had an average progression-free survival of 24.8 months, compared to 8.3 months for those given a placebo. He also noted that women with advanced ovarian cancer have a low prognosis, with a global five-year survival rate of less than 50% and a recurrence rate of approximately 75%.

The drug is accessible to women, regardless of their BRCA gene mutation status. Both BRCA positive and BRCA negative women can receive the drug if they have not previously been prescribed PARP Inhibitors as part of their treatment.

Niraparib, also known as Zejula, is a PARP inhibitor, a targeted cancer drug used to treat certain types of ovarian, fallopian tube, or primary peritoneal cancers.

At the 4-year mark, patients who received Niraparib had a higher likelihood of being free from progression or death compared to those who received a placebo (38% versus 17%). Overall, the percentage of patients who were free from progression or death was 24% in the Niraparib group compared to 14% in the placebo group.

The use of niraparib is recommended within the Cancer Drugs Fund as a treatment option for individuals with advanced (FIGO stages 3 and 4) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer. This recommendation is applicable after the patient has responded to first-line platinum-based chemotherapy, provided that the conditions outlined in the managed access agreement are adhered to.

The REVOCAN trial aims to recruit 26 female participants who have been utilizing Zejula by Tesaro as a second-line maintenance therapy for a minimum of six months. These individuals must have also encountered an increase in the ovarian cancer biomarker CA125, which could indicate that the cancer is advancing while on Zejula.

After responding to first-line platinum-based chemotherapy, a wide range of newly diagnosed advanced ovarian cancer patients can significantly reduce their risk of disease progression or death through Niraparib maintenance.

In September 2022, a decision was made to voluntarily withdraw niraparib as a treatment option for adults with advanced platinum-sensitive epithelial ovarian cancer. This withdrawal applies to patients who have undergone three or more chemotherapy regimens and whose cancer is linked to a positive status of homologous recombination deficiency.

Niraparib had the lowest average monthly cost of $11,723, which was 11% and 27% lower than the costs of olaparib ($13,015) and rucaparib ($14,893), respectively.

Our meta-analysis found that niraparib maintenance was significantly associated with haematological toxicities such as thrombocytopenia, anemia, and neutropenia, as well as gastrointestinal toxicities including nausea, vomiting, and constipation. These adverse effects were observed across all grades and were statistically significant.

Niraparib, also known as Zejula, is a maintenance therapy used for ovarian cancer. While it does not provide a cure for the disease, it effectively slows down its progression. By delaying the spread of ovarian cancer, Niraparib improves the overall well-being of women and allows them to lead healthier lives for an extended period of time, resulting in reduced symptoms.

Initially, the combination of surgery and chemotherapy can lead to remission in most patients. However, the challenge lies in the fact that ovarian cancer tends to recur due to the presence of minimal residual disease. This refers to the presence of microscopic amounts of cancer cells in the body that are currently undetectable by our existing scans and tests.

Regular visits to your doctor are crucial for monitoring your progress. This will enable your doctor to assess the effectiveness of the medication and determine whether it should be continued. Additionally, blood tests may be necessary to identify any potential adverse effects.

If you experience a severe sunburn or skin reaction like itching, rash, or swelling after sun exposure, inform your healthcare team as your skin may be more susceptible to sunburn than usual. It is important to note that hair loss is not a side effect of niraparib. For a copy of further information, kindly ask your nurse or pharmacist.

Niraparib, also referred to as Zejula, serves as a maintenance therapy for ovarian cancer. While it does not provide a cure for the disease, it effectively inhibits its advancement.

Treatment options for epithelial ovarian cancer depend on the stage of the cancer. For stage 1 epithelial ovarian cancer, surgery alone is typically the main treatment option. However, chemotherapy may be recommended after surgery if there is a high risk of the cancer recurring.

For stages 2, 3, and 4 epithelial ovarian cancer, a combination of surgery and chemotherapy is usually the standard treatment approach. Surgery is performed to remove as much of the cancer as possible, followed by chemotherapy to target any remaining cancer cells and reduce the risk of recurrence.

The long-term safety data from the NOVA trial has confirmed that niraparib is well tolerated with appropriate adjustments to the dosage. The occurrence of adverse events that resulted in dose reductions was highest in the first month and gradually decreased over the course of 48 months. Similarly, dose interruptions followed a similar pattern.

Preventing a recurrence of ovarian cancer is challenging as there is no definitive method. There is no specific diet, vitamin, or regimen that has been proven to prevent recurrence. However, it is advisable to maintain good health by following a nutritious diet and staying physically active.

NIRAPARIB (nye RAP a rib) is a chemotherapy medication that inhibits the growth of cancer cells by targeting specific enzymes within them. It is prescribed for the treatment of ovarian cancer, fallopian tube cancer, and peritoneal cancer.

ZEJULA is a single tablet taken once a day that has been proven to help delay the recurrence of cancer in certain patients, and is not classified as chemotherapy.

Zejula has a first-line maintenance indication, which is not at risk from the adcom. It has an all-comers label, meaning it can be used for a wider range of patients. On the other hand, Lynparza is limited to patients who are Brca-positive or HRD-positive when combined with Avastin.

Niraparib, also known as Zejula, is a PARP inhibitor, a targeted cancer drug used to treat certain types of ovarian, fallopian tube, or primary peritoneal cancers.

“He said that Genentech can price Avastin high, which is why it is expensive. However, the price is comparable to other cancer drugs,” Mr. Schmidt explained. He also mentioned that despite the high costs of research and development, Genentech is one of the most profitable companies in the pharmaceutical and biotechnology industry.

Zejula has the ability to penetrate the blood brain barrier, which is a specialized barrier that protects the central nervous system (consisting of the brain and spinal cord) from the general circulation of blood.

To summarize, the results indicate that both olaparib and niraparib maintenance therapy have a significant impact on prolonging overall survival (OS) in patients with gBRCA mutations. Additionally, olaparib has a clear effect in extending OS in the general population. Furthermore, all three PARP inhibitors as monotherapy can effectively prolong progression-free survival (PFS) without any notable differences in efficacy.

To enhance the treatment plan for patients diagnosed with stage III or IV ovarian cancer, it is recommended to incorporate Avastin starting from cycle 2 following primary surgery. Subsequently, the patients should continue with Avastin as a single-agent therapy for a maximum of 22 cycles.

This study discovered that niraparib maintenance therapy effectively decreased the likelihood of disease progression or death compared to a placebo in a diverse group of patients with newly diagnosed advanced ovarian cancer. This was observed after the patients had responded to initial treatment with platinum-based chemotherapy, regardless of other factors.

The duration of maintenance therapy depends on various factors. For potentially curable cancers in remission, maintenance treatment is typically administered for a specific period, typically ranging from 6 weeks to 2 years.

If you have any serious bleeding problems, you should not be given this medication. Additionally, there is a rare possibility that this medication may cause a tear in the stomach or intestines, known as gastrointestinal perforation.

Zejula and Rubraca are both PARP inhibitors, with Zejula containing niraparib and Rubraca containing rucaparib. PARP inhibitors are a class of drugs that work in a similar way.